Bifidobacterium BLa80 mitigates colitis by altering gut microbiota and alleviating inflammation
Authors:
Open Access
- 7 June 2022
- journal article
- research article
- Published by Springer Nature in AMB Express
- Vol. 12 (1) , 1-10
Abstract
This study was conducted to explore the therapeutic effect of the probioticBifidobacterium animalissubsp.lactisBLa80 on inflammatory bowel disease. A model of ulcerative colitis (UC) was induced in C57BL/6 mice by administering of 2.5% dextran sulphate sodium (DSS) for 8 days. After developing UC, some mice were treated via intragastric administration of BLa80 at a dose of 109colony-forming units to assess the preventive effects of BLa80 on DSS-induced UC. Compared with non-treated UC model mice, BLa80-treated mice had reduced colon shortening and improvements in colonic tissue structure. Treatment with BLa80 also decreased the serum concentrations of the proinflammatory cytokines tumor necrosis factor-alpha (TNF-α), interleukin (IL) 6 and IL-17 in mice. 16S rRNA gene sequencing revealed that BLa80 increased gut microbial diversity in mice and modulated UC-associated imbalances in the gut microbiota. BLa80 selectively promoted the growth of beneficial bacteria, includingRomboutsiaandAdlercreutzia, the abundances of which were negatively correlated with concentration of cellular inflammatory factors. In summary, the study results demonstrated that pretreatment withB.lactisBLa80 reduced intestinal inflammation and altered the gut microbiota, implying that BLa80 is a promising probiotic strain with potential therapeutic function in UC.Keywords
Funding Information
- Natural Science Foundation of Shanghai Municipality (20ZR1440200)
- Postdoctoral Research Foundation of China (2021M691340)
- Shanghai Engineering Center of Dairy Biotechnology ((19DZ2281400))
- The National 13th Five-Year Plan (2019YFC1605803)
This publication has 51 references indexed in Scilit:
- Predictive functional profiling of microbial communities using 16S rRNA marker gene sequencesNature Biotechnology, 2013
- Natural Products as a Source of Anti-Inflammatory Agents Associated with Inflammatory Bowel DiseaseMolecules, 2013
- Host-microbial interactions and regulation of intestinal epithelial barrier function: From physiology to pathologyWorld Journal of Gastrointestinal Pathophysiology, 2012
- Metagenomic biomarker discovery and explanationGenome Biology, 2011
- Genetics and pathogenesis of inflammatory bowel diseaseNature, 2011
- Anti-inflammatory effects of dietary phenolic compounds in an in vitro model of inflamed human intestinal epitheliumChemico-Biological Interactions, 2010
- Regulation of CCL2 and CCL3 expression in human brain endothelial cells by cytokines and lipopolysaccharideJournal of Neuroinflammation, 2010
- Neuroinflammation in inflammatory bowel diseaseJournal of Neuroinflammation, 2010
- Ulcerative proctitis: a review of pharmacotherapy and managementExpert Opinion on Pharmacotherapy, 2008
- Unravelling the pathogenesis of inflammatory bowel diseaseNature, 2007